Pneumonia is indicated as a complex infection, which affects the lower part of the respiratory tract along with deposition of cough in the lungs. It may even occur as a consequence to an upper tract infection. Frequently, it occurs in people with weakened immunity, and in geriatric population and children. Biotechnological methods can be approached for testing of pneumonia such as enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR). The global pneumonia testing market was valued at $932 million in 2016, and is estimated to reach $1,738 million by 2023, registering a CAGR of 9.2% from 2017 to 2023. Research Beam Model: Research Beam Product ID: 2733651 5370 USD New
Pneumonia Testing Market by Method (Immunodiagnostics, Molecular Diagnostics, and Point of Care Testing), Technology (Enzyme Linked Immunosorbent Assay, Immunofluorescence, Western Blot, Polymerase Chain Reaction, Immunohistochemistry, and Others), Type (Analyzers and Consumables), and End User (Hospitals, Diagnostic Laboratories, Homecare, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

Pneumonia Testing Market by Method (Immunodiagnostics, Molecular Diagnostics, and Point of Care Testing), Technology (Enzyme Linked Immunosorbent Assay, Immunofluorescence, Western Blot, Polymerase Chain Reaction, Immunohistochemistry, and Others), Type (Analyzers and Consumables), and End User (Hospitals, Diagnostic Laboratories, Homecare, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

 
  • Category : Healthcare
  • Published On : November  2017
  • Pages : 243
 
 

Pneumonia is indicated as a complex infection, which affects the lower part of the respiratory tract along with deposition of cough in the lungs. It may even occur as a consequence to an upper tract infection. Frequently, it occurs in people with weakened immunity, and in geriatric population and children. Biotechnological methods can be approached for testing of pneumonia such as enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR). The global pneumonia testing market was valued at $932 million in 2016, and is estimated to reach $1,738 million by 2023, registering a CAGR of 9.2% from 2017 to 2023. 

The report segments the pneumonia testing market by method, type, technology, end user, and region. In terms of method, the market is classified into immunodiagnostics, molecular diagnostics, and point-of-care (POC) testing. Based on technology, it is categorized into enzyme-linked immunosorbent assay (ELISA), immunofluorescence, western blot, polymerase chain reaction (PCR), immunohistochemistry (IHC), and others. By type, it is bifurcated into analyzers and consumables. Depending on end user, it is divided into hospitals, diagnostic laboratories, homecare, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Increased awareness regarding early diagnosis, rise in popularity of POC testing, and surge in government expenditures on healthcare. However, limited detection capability and accuracy of some of the pneumonia testing products and regulatory and economic hurdles hamper the market growth. Some of the factors such as increase in adoption of molecular diagnostic testing and untapped markets in developing economies could open avenues of opportunities for the pneumonia testing market.

KEY MARKET BENEFITS

  • This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
  • The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
  • In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY PLAYERS PROFILED

  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • F-Hoffmann la Roche Ltd.
  • Hologic Inc.
  • bioMerieux
  • Becton, Dickenson and Company
  • Bio-Rad Laboratories Inc.
  • Meridian Biosciences
  • Quest Diagnostics
  • Quidel

Pneumonia Testing Market key SEGMENTS:

By Method 

  • Immunodiagnostics
  • Molecular Diagnostics
  • Point of Care (POC) Testing

By Technology

  • Enzyme-linked Immunosorbent Assay (ELISA)
  •  Immunofluorescence
  •  Western Blot
  •  Polymerase Chain Reaction (PCR)
  •  Immunohistochemistry (IHC)
  •  Others

By Type

  •  Analyzers
  •  Consumables

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Homecare
  • Others

 By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

The other players of the pneumonia testing market include (companies not profiled in the report):

  • AdvanDx
  • Beckman Coulter
  • Cepheid
  • Concile
  • Diamedix
  • DiaSorin
  • Fast-track Diagnostics
  • SeraCare
  • Trinity Biotech.

CHAPTER 1 INTRODUCTION

1.1. KEY BENEFITS
1.2. KEY MARKET SEGMENTS
1.3. RESEARCH METHODOLOGY

1.3.1. Secondary research
1.3.2. Primary research
1.3.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets, 2016
3.2.2. Top winning strategies

3.3. TOP PLAYER POSITIONING, 2016
3.4. PORTERS FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Surge in awareness towards early diagnosis
3.5.1.2. Rise in popularity of POC testing
3.5.1.3. Increase in government expenditure on healthcare

3.5.2. Restraints

3.5.2.1. Limited detection capability and accuracy
3.5.2.2. Regulatory and economic hurdles

3.5.3. Opportunities

3.5.3.1. Increase in adoption of molecular diagnostic testing
3.5.3.2. Untapped markets in the developing economies

CHAPTER 4 PNEUMONIA TESTING MARKET, BY METHOD

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. IMMUNODIAGNOSTICS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. MOLECULAR DIAGNOSTICS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. POINT-OF-CARE (POC) TESTING

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 PNEUMONIA TESTING MARKET, BY TECHNOLOGY

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)

5.2.1. Market size and forecast

5.3. IMMUNOFLUORESCENCE

5.3.1. Market size and forecast

5.4. WESTERN BLOT

5.4.1. Market size and forecast

5.5. POLYMERASE CHAIN REACTION (PCR)

5.5.1. Market size and forecast

5.6. IMMUNOHISTOCHEMISTRY (IHC)

5.6.1. Market size and forecast

5.7. OTHERS

5.7.1. Market size and forecast

CHAPTER 6 PNEUMONIA TESTING MARKET, BY TYPE

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. ANALYZERS

6.2.1. Market size and forecast

6.3. CONSUMABLES

6.3.1. Market size and forecast

CHAPTER 7 PNEUMONIA TESTING MARKET, BY END USER

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. HOSPITALS

7.2.1. Market size and forecast

7.3. DIAGNOSTIC CENTERS

7.3.1. Market size and forecast

7.4. HOMECARE

7.4.1. Market size and forecast

7.5. OTHERS

7.5.1. Market size and forecast

CHAPTER 8 PNEUMONIA TESTING MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast, by method
8.2.4. Market size and forecast, by technology
8.2.5. Market size and forecast, by type
8.2.6. Market size and forecast, by end user
8.2.7. Market size and forecast, by country

8.2.7.1. U.S. market size and forecast, by method
8.2.7.2. U.S. market size and forecast, by technology
8.2.7.3. U.S. market size and forecast, by type
8.2.7.4. U.S. market size and forecast, by end user
8.2.7.5. Canada market size and forecast, by method
8.2.7.6. Canada market size and forecast, by technology
8.2.7.7. Canada market size and forecast, by type
8.2.7.8. Canada market size and forecast, by end user
8.2.7.9. Mexico market size and forecast, by method
8.2.7.10. Mexico market size and forecast, by technology
8.2.7.11. Mexico market size and forecast, by type
8.2.7.12. Mexico market size and forecast, by end user

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast, by method
8.3.4. Market size and forecast, by technology
8.3.5. Market size and forecast, by type
8.3.6. Market size and forecast, by end user
8.3.7. Market size and forecast, by country

8.3.7.1. Germany market size and forecast, by method
8.3.7.2. Germany market size and forecast, by technology
8.3.7.3. Germany market size and forecast, by type
8.3.7.4. Germany market size and forecast, by end user
8.3.7.5. France market size and forecast, by method
8.3.7.6. France market size and forecast, by technology
8.3.7.7. France market size and forecast, by type
8.3.7.8. France market size and forecast, by end user
8.3.7.9. UK market size and forecast, by method
8.3.7.10. UK market size and forecast, by technology
8.3.7.11. UK market size and forecast, by type
8.3.7.12. UK market size and forecast, by end user
8.3.7.13. Italy market size and forecast, by method
8.3.7.14. Italy market size and forecast, by technology
8.3.7.15. Italy market size and forecast, by type
8.3.7.16. Italy market size and forecast, by end user
8.3.7.17. Spain market size and forecast, by method
8.3.7.18. Spain market size and forecast, by technology
8.3.7.19. Spain market size and forecast, by type
8.3.7.20. Spain market size and forecast, by end user
8.3.7.21. Rest of Europe market size and forecast, by method
8.3.7.22. Rest of Europe market size and forecast, by technology
8.3.7.23. Rest of Europe market size and forecast, by type
8.3.7.24. Rest of Europe market size and forecast, by end user

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast, by method
8.4.4. Market size and forecast, by technology
8.4.5. Market size and forecast, by type
8.4.6. Market size and forecast, by end user
8.4.7. Market size and forecast, by country

8.4.7.1. Japan market size and forecast, by method
8.4.7.2. Japan market size and forecast, by technology
8.4.7.3. Japan market size and forecast, by type
8.4.7.4. Japan market size and forecast, by end user
8.4.7.5. China market size and forecast, by method
8.4.7.6. China market size and forecast, by technology
8.4.7.7. China market size and forecast, by type
8.4.7.8. China market size and forecast, by end user
8.4.7.9. Australia market size and forecast, by method
8.4.7.10. Australia market size and forecast, by technology
8.4.7.11. Australia market size and forecast, by type
8.4.7.12. Australia market size and forecast, by end user
8.4.7.13. India market size and forecast, by method
8.4.7.14. India market size and forecast, by technology
8.4.7.15. India market size and forecast, by type
8.4.7.16. India market size and forecast, by end user
8.4.7.17. South Korea market size and forecast, by method
8.4.7.18. South Korea market size and forecast, by technology
8.4.7.19. South Korea market size and forecast, by type
8.4.7.20. South Korea market size and forecast, by end user
8.4.7.21. Taiwan market size and forecast, by method
8.4.7.22. Taiwan market size and forecast, by technology
8.4.7.23. Taiwan market size and forecast, by type
8.4.7.24. Taiwan market size and forecast, by end user
8.4.7.25. Rest of Asia-Pacific market size and forecast, by method
8.4.7.26. Rest of Asia-Pacific market size and forecast, by technology
8.4.7.27. Rest of Asia-Pacific market size and forecast, by type
8.4.7.28. Rest of Asia-Pacific market size and forecast, by end user

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast, by method
8.5.4. Market size and forecast, by technology
8.5.5. Market size and forecast, by type
8.5.6. Market size and forecast, by end user
8.5.7. Market size and forecast, by country

8.5.7.1. Brazil market size and forecast, by method
8.5.7.2. Brazil market size and forecast, by technology
8.5.7.3. Brazil market size and forecast, by type
8.5.7.4. Brazil market size and forecast, by end user
8.5.7.5. Saudi Arabia market size and forecast, by method
8.5.7.6. Saudi Arabia market size and forecast, by technology
8.5.7.7. Saudi Arabia market size and forecast, by type
8.5.7.8. Saudi Arabia market size and forecast, by end user
8.5.7.9. South Africa market size and forecast, by method
8.5.7.10. South Africa market size and forecast, by technology
8.5.7.11. South Africa market size and forecast, by type
8.5.7.12. South Africa market size and forecast, by end user
8.5.7.13. Rest of LAMEA market size and forecast, by method
8.5.7.14. Rest of LAMEA market size and forecast, by technology
8.5.7.15. Rest of LAMEA market size and forecast, by type
8.5.7.16. Rest of LAMEA market size and forecast, by end user

CHAPTER 9 COMPANY PROFILES

9.1. ABBOTT LABORATORIES

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.1.5. Key strategic moves and developments

9.2. BECTON, DICKINSON AND COMPANY

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segment
9.2.4. Business performance
9.2.5. Key strategic moves and developments

9.3. BIOMERIEUX S.A.

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating product solutions
9.3.4. Business performance
9.3.5. Key strategic moves and developments

9.4. BIO-RAD LABORATORIES, INC.

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance

9.5. F. HOFFMANN-LA ROCHE AG

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Business performance
9.5.5. Key strategic moves and developments

9.6. HOLOGIC, INC.

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance
9.6.5. Key strategic moves and developments

9.7. MERIDIAN BIOSCIENCE, INC.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments

9.8. QUEST DIAGNOSTICS INCORPORATED

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance

9.9. QUIDEL CORPORATION

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Business performance
9.9.4. Key strategic moves and developments

9.10. THERMO FISHER SCIENTIFIC INC.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Business performance

LIST OF TABLES

TABLE 1. GLOBAL PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 2. METHODS AND SAMPLES USED IN IMMUNODIAGNOSTIC METHODS FOR PNEUMONIA TESTING
TABLE 3. IMMUNODIAGNOSTICS PNEUMONIA TESTING MARKET, BY, GEOGRAPHY 2016-2023 ($MILLION)
TABLE 4. MOLECULAR DIAGNOSTICS PNEUMONIA TESTING MARKET, BY GEOGRAPHY 2016-2023 ($MILLION)
TABLE 5. POINT-OF-CARE PNEUMONIA TESTING MARKET, BY, GEOGRAPHY 2016-2023 ($MILLION)
TABLE 6. GLOBAL PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 7. COMMONLY USED ELISA PRODUCTS AND THEIR COMPANY NAMES
TABLE 8. PNEUMONIA TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GEOGRAPHY 2016-2023 ($MILLION)
TABLE 9. PNEUMONIA TESTING MARKET FOR IMMUNOFLUORESCENCE, BY GEOGRAPHY 2016-2023 ($MILLION)
TABLE 10. PNEUMONIA TESTING MARKET FOR WESTERN BLOT, BY GEOGRAPHY 2016-2023 ($MILLION)
TABLE 11. PNEUMONIA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY GEOGRAPHY 2016-2023 ($MILLION)
TABLE 12. PNEUMONIA TESTING MARKET FOR IMMUNOHISTOCHEMISTRY, BY GEOGRAPHY 2016-2023 ($MILLION)
TABLE 13. COMMONLY USED OTHER TECHNOLOGY PRODUCTS AND THEIR COMPANY NAMES
TABLE 14. PNEUMONIA TESTING MARKET FOR OTHERS TECHNOLOGIES, BY GEOGRAPHY 2016-2023 ($MILLION)
TABLE 15. GLOBAL PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 16. PNEUMONIA TESTING MARKET FOR ANALYZERS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 17. PNEUMONIA TESTING MARKET FOR CONSUMABLES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 18. GLOBAL PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 19. PNEUMONIA TESTING MARKET FOR HOSPITALS, BY GEOGRAPHY 2016-2023 ($MILLION)
TABLE 20. PNEUMONIA TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY GEOGRAPHY 2016-2023 ($MILLION)
TABLE 21. PNEUMONIA TESTING MARKET FOR HOMECARE, BY GEOGRAPHY 2016-2023 ($MILLION)
TABLE 22. PNEUMONIA TESTING MARKET FOR OTHERS, BY GEOGRAPHY 2016-2023 ($MILLION)
TABLE 23. PNEUMONIA TESTING MARKET, BY GEOGRAPHY 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 25. NORTH AMERICA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 26. NORTH AMERICA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 27. NORTH AMERICA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 28. NORTH AMERICA PNEUMONIA TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 29. U.S. PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 30. U.S. PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 31. U.S. PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 32. U.S. PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 33. CANADA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 34. CANADA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 35. CANADA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 36. CANADA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 37. MEXICO PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 38. MEXICO PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 39. MEXICO PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 40. MEXICO PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 41. EUROPE PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 42. EUROPE PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 43. EUROPE PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 44. EUROPE PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 45. EUROPE PNEUMONIA TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 46. GERMANY PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 47. GERMANY PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 48. GERMANY PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 49. GERMANY PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 50. FRANCE PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 51. FRANCE PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 52. FRANCE PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 53. FRANCE PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 54. UK PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 55. UK PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 56. UK PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 57. UK PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 58. ITALY PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 59. ITALY PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 60. ITALY PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 61. ITALY PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 62. SPAIN PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 63. SPAIN PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 64. SPAIN PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 65. SPAIN PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 66. REST OF EUROPE PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 67. REST OF EUROPE PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 68. REST OF EUROPE PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 69. REST OF EUROPE PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 70. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 71. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 72. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 73. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 74. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 75. JAPAN PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 76. JAPAN PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 77. JAPAN PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 78. JAPAN PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 79. CHINA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 80. CHINA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 81. CHINA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 82. CHINA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 83. AUSTRALIA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 84. AUSTRALIA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 85. AUSTRALIA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 86. AUSTRALIA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 87. INDIA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 88. INDIA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 89. INDIA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 90. INDIA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 91. SOUTH KOREA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 92. SOUTH KOREA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 93. SOUTH KOREA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 94. SOUTH KOREA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 95. TAIWAN PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 96. TAIWAN PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 97. TAIWAN PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 98. TAIWAN PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 99. REST OF ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 100. REST OF ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 101. REST OF ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 102. REST OF ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 103. LAMEA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 104. LAMEA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 105. LAMEA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 106. LAMEA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 107. LAMEA PNEUMONIA TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 108. BRAZIL PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 109. BRAZIL PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 110. BRAZIL PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 111. BRAZIL PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 112. SAUDI ARABIA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 113. SAUDI ARABIA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 114. SAUDI ARABIA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 115. SAUDI ARABIA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 116. SOUTH AFRICA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 117. SOUTH AFRICA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 118. SOUTH AFRICA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 119. SOUTH AFRICA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 120. REST OF LAMEA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)
TABLE 121. REST OF LAMEA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 122. REST OF LAMEA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 123. REST OF LAMEA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 124. ABBOTT: COMPANY SNAPSHOT
TABLE 125. ABBOTT: OPERATING SEGMENTS
TABLE 126. BD: COMPANY SNAPSHOT
TABLE 127. BD: OPERATING SEGMENTS
TABLE 128. BIOMERIEUX S.A.: COMPANY SNAPSHOT
TABLE 129. BIOMRIEUX: PRODUCT SOLUTIONS
TABLE 130. BIO-RAD: COMPANY SNAPSHOT
TABLE 131. BIO-RAD: OPERATING SEGMENTS
TABLE 132. ROCHE: COMPANY SNAPSHOT
TABLE 133. ROCHE: OPERATING SEGMENT
TABLE 134. HOLOGIC: COMPANY SNAPSHOT
TABLE 135. HOLOGIC: OPERATING SEGMENTS
TABLE 136. MERIDIAN: COMPANY SNAPSHOT
TABLE 137. MERIDIAN: OPERATING SEGMENTS
TABLE 138. QUEST DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 139. QUEST DIAGNOSTICS: OPERATING SEGMENTS
TABLE 140. QUIDEL CORPORATION: COMPANY SNAPSHOT
TABLE 141. THERMO FISHER: COMPANY SNAPSHOT
TABLE 142. THERMO FISHER: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 1. GLOBAL PNEUMONIA TESTING MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS, BY TECHNOLOGY, 2016
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP PLAYER POSITIONING, 2016
FIGURE 6. LOW BARGAINING POWER OF BUYERS
FIGURE 7. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 8. LOW THREAT OF NEW ENTRANTS
FIGURE 9. LOW THREAT OF SUBSTITUTION
FIGURE 10. HIGH COMPETITIVE RIVALRY
FIGURE 11. GLOBAL PNEUMONIA TESTING MARKET: RESTRAINTS AND DRIVERS
FIGURE 12. PNEUMONIA TESTING MARKET, SEGMENTATION BY METHOD
FIGURE 13. PNEUMONIA TESTING MARKET, SEGMENTATION BY TECHNOLOGY
FIGURE 14. PNEUMONIA TESTING MARKET, SEGMENTATION BY TYPE
FIGURE 15. PNEUMONIA TESTING MARKET, SEGMENTATION BY END USER
FIGURE 16. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 17. ABBOTT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 18. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 19. BD: NET SALES, 2014-2016 ($MILLION)
FIGURE 20. BD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 21. BD: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 22. BIOMERIEUX S.A.: NET SALES, 2014-2016 ($MILLION)
FIGURE 23. BIOMERIEUX S.A.: REVENUE SHARE BY APPLICATION, 2016 (%)
FIGURE 24. BIOMERIEUX S.A.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25. BIO-RAD: NET SALES, 2014-2016 ($MILLION)
FIGURE 26. BIO-RAD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 27. BIORAD: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 28. ROCHE: NET SALES, 2014-2016 ($MILLION)
FIGURE 29. ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 30. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 31. HOLOGIC: NET SALES, 2014-2016 ($MILLION)
FIGURE 32. HOLOGIC: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 33. HOLOGIC: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 34. MERIDIAN: NET SALES, 2015-2017 ($MILLION)
FIGURE 35. QUEST DIAGNOSTICS: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. QUEST DIAGNOSTICS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 37. QUIDEL CORPORATION: NET SALES, 2014-2016 ($MILLION)
FIGURE 38. QUIDEL CORPORATION: REVENUE SHARE BY PRODUCT CATEGORY, 2016 (%)
FIGURE 39. QUIDEL CORPORATION: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 40. THERMO FISHER: NET SALES, 2014-2016 ($MILLION)
FIGURE 41. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 42. THERMO FISHER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)